Study guide
Cardiometabolic and Organ System Monitoring
CDCES Certified Diabetes Care and Education Specialist
Track your progress as you read
Finished sections get a check mark.
1 Introduction & the CDCES Exam
About the CDCES Credential & Current Exam Facts The July 2024 Exam Content Outline & Domain Weights The ADCES7 Self-Care Behaviors Framework
2 Pathophysiology, Classification & Diagnosis
Normal Glucose Regulation and the Pathophysiology of T1DM and T2DM Classification and Diagnostic Criteria Risk Factors and Primary Prevention Treatment Goals and Glycemic Targets
3 Assessment: History, Physical & Data
Health History & Diabetes-Specific Physical Assessment Interpreting Diabetes Measures & Laboratory Data Social Determinants of Health & Psychosocial Wellbeing
4 Assessing Self-Management & Learning
Assessing Self-Management Behaviors & Knowledge Assessing Technology Use, Problem-Solving & Risk-Reduction Behaviors Assessing Learning: Goals, Readiness to Change & Literacy Learning Considerations & Barriers
5 Developing the Education & Care Plan
Developing the Individualized Education/Care Plan Instructional Methods & Person-Centered Teaching Strategies SMART Goals, Behavior-Change Theory & Motivational Interviewing
6 Nutrition Therapy
Nutrition Recommendations & Eating Patterns Carbohydrate Counting & Insulin-Food Timing Fats, Protein, Alcohol & Dietary Supplements Food Labels, Weight Management & Special Nutrition Considerations
7 Physical Activity
Physical Activity Recommendations, Benefits, Challenges & Safety Activity Planning with FITT and Adjusting for Planned & Unplanned Activity
8 Pharmacologic Therapy
Insulin — Types, Pharmacokinetics & Delivery Systems Non-Insulin Glucose-Lowering Agents Guideline-Based Medication Selection Medication Titration & Immunizations for People with Diabetes
9 Monitoring
Glucose Monitoring: SMBG, CGM & Time in Range A1C and Ketone Monitoring Cardiometabolic and Organ System Monitoring
10 Acute Complications
Hypoglycemia Hyperglycemia, DKA, and HHS
11 Chronic Complications
Screening Schedules and Microvascular Disease Macrovascular Disease and Lower-Extremity Foot Care Infections, Dental Disease, Sexual Dysfunction, and Other Comorbidities
12 Special Situations & Populations
Sick-Day Management, Surgery, Travel & Emergency Preparedness Special Populations Across the Lifespan Preconception, Pregnancy, Postpartum & Gestational Diabetes Daily Living, Psychosocial Wellbeing & Safety
13 Evaluation & Documentation
Evaluating Intervention Effectiveness & Outcomes Documentation, Plan Revision & Referral
14 Standards, Guidelines & Professional Practice
National Standards for DSMES and the National DPP Applying Evidence-Based Practice Guidelines Population Health, Health Equity & Advocacy
Cardiometabolic and Organ System Monitoring
Key Takeaways Explain This Topic AI
Blood pressure should be measured at every routine diabetes visit, at minimum every 6 months, per ADA Standards of Care.
A lipid panel is recommended at diagnosis and at least every 5 years thereafter for adults under 40 not on a statin.
Kidney monitoring requires both eGFR and urine albumin-to-creatinine ratio (UACR) at least annually, starting at diagnosis for type 2 diabetes and 5 years post-diagnosis for type 1 diabetes.
Once chronic kidney disease is identified, eGFR and UACR monitoring frequency increases to 1-4 times per year based on CKD stage.
ADA recommends FIB-4 liver fibrosis screening for all adults with type 2 diabetes or prediabetes regardless of liver enzyme levels, since normal ALT/AST does not rule out fibrosis.
Last updated: July 2026
Blood Pressure and Weight
Hypertension is the most common diabetes comorbidity and a major driver of both macrovascular and microvascular complications. ADA Standards of Care recommend blood pressure be measured at every routine clinical visit , at minimum every 6 months, using proper technique — seated, back supported, feet flat, arm at heart level, after 5 minutes of rest. Home blood pressure monitoring is encouraged to confirm office readings and detect white-coat or masked hypertension. Hypertension is diagnosed at a confirmed average of 130/80 mmHg or higher across two or more readings on two or more separate occasions; a reading of 120-129 systolic with diastolic under 80 (elevated, not yet diagnostic) should prompt repeat confirmation rather than an immediate diagnosis.
Weight and BMI should be assessed at every visit — weight trends inform medication selection (many GLP-1- and GIP-based therapies are weight-favorable, while some sulfonylureas and thiazolidinediones promote weight gain), flag unintentional weight loss (a red flag for uncontrolled hyperglycemia or an alternate diagnosis), and track progress toward individualized weight goals.
Lipid Monitoring
A lipid panel should be obtained at diabetes diagnosis, at the initial comprehensive medical evaluation, and at minimum every 5 years thereafter in adults under 40 not on lipid-lowering therapy; more frequent panels are reasonable in younger people with long diabetes duration, such as youth-onset type 1 diabetes, or in anyone with worsening cardiovascular risk. Once statin therapy starts, LDL cholesterol should be rechecked 4-12 weeks after initiation or any dose change, then annually to monitor adherence and response.
Kidney Monitoring
Diabetic kidney disease is screened with two complementary tests that must both be obtained: estimated glomerular filtration rate (eGFR) , calculated from serum creatinine, and urine albumin-to-creatinine ratio (UACR) , a spot urine sample. Both should be measured at least annually — starting at diagnosis for type 2 diabetes and beginning 5 years after diagnosis for type 1 diabetes. Once chronic kidney disease (CKD) is identified, monitoring frequency increases to 1-4 times per year depending on CKD stage and severity, which guides nephrology referral timing and medication adjustments such as renally-cleared drug dosing and cardiorenal-protective agent selection (Chapter 8).
- Organ System Test(s) Baseline Timing Ongoing Frequency
- Blood pressure BP measurement Every visit At least every 6 months
- Weight/BMI Weight, BMI Every visit Every visit
Lipids Lipid panel At diagnosis + initial evaluation At least every 5 years (under 40, no statin); annually once on a statin
- Kidney eGFR + UACR T2D at diagnosis; T1D at 5 years post-diagnosis Annually; 1-4x/year once CKD is present
- Liver FIB-4 (± VCTE or ELF if elevated) At diagnosis/initial evaluation Every 1-3 years if low risk
- Hepatic Monitoring
Because metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) affects a majority of people with type 2 diabetes, ADA now recommends screening all adults with type 2 diabetes or prediabetes for liver fibrosis regardless of liver enzyme levels — normal ALT and AST do not rule out significant fibrosis. The first-line tool is the FIB-4 index , calculated from age, AST, ALT, and platelet count. A low-risk FIB-4 score allows primary-care management with rescreening roughly every 1-3 years ; a FIB-4 score at or above the risk threshold triggers a second-line test — liver stiffness measurement by vibration-controlled transient elastography (VCTE), or the Enhanced Liver Fibrosis (ELF) test — to determine whether hepatology referral is warranted.
The FIB-4 index is calculated as (age × AST) ÷ (platelet count × √ALT), producing a score that stratifies fibrosis risk: below 1.30 (below 2.0 in adults 65 and older) is low risk, 1.30-2.67 (2.0-2.67 if 65 or older) is indeterminate, and above 2.67 is high risk. The CDCES does not calculate FIB-4 independently but should recognize the score on a lab report or patient portal and know that an indeterminate or high-risk result routes the person to further testing or hepatology referral rather than reassurance.
Home Monitoring Between Visits
Home monitoring extends the clinic schedule between visits. A validated, properly sized home blood pressure cuff — arm circumference matters, since an undersized cuff falsely elevates readings — lets the person track trends and bring several weeks of home readings to each visit. Home scales support weight-trend tracking between annual labs. The CDCES teaches correct home BP technique (same arm, same time of day, seated and rested after 5 minutes) and reinforces that home readings supplement, rather than replace, the clinic and laboratory schedule described above.
The CDCES Role Across These Metrics
No monitoring result exists in isolation. The CDCES integrates blood pressure, weight, lipid, kidney, and hepatic trends into the same person-centered education plan used for glycemic metrics (Chapter 5): explaining why each test matters, what an abnormal result means for daily self-care, and how results connect to medication selection (Chapter 8) and complication risk reduction (Chapter 11). Missed or overdue monitoring is itself a self-management barrier worth assessing (Chapter 4) — cost, transportation, and health literacy are common reasons people fall out of the recommended monitoring cadence.